Bladder and Kidney Cancer: Immunotherapy, Antibody Conjugates and Anti-Angiogenics
One of these cancers is treated by dripping a live tuberculosis vaccine straight into the bladder. Its neighbour, kidney cancer, shrugs off conventional chemotherapy so completely that oncologists gave up on it — and instead learned to starve the tumour's blood supply and set the immune system loose. This is the genitourinary story: an organ system where the classic rule 'cancer means chemotherapy' quietly broke, and something smarter took its place.
A 63-year-old presents with a mass in her kidney; the scan shows it has already spread to the lungs. The oncology resident reaches for the reflex — which chemotherapy regimen? The attending stops him. "Not this one. Renal cell carcinoma doesn't care about your cytotoxics." And it's true: give this tumour conventional chemotherapy and it barely blinks. So instead they do something that would have sounded like science fiction a generation ago — they hand her a pill that strangles the tumour's blood vessels, and an infusion that unleashes her own T-cells against it. No classic chemo at all. Kidney cancer is the tumour that rewrote the rule that 'cancer equals chemotherapy' — and to understand why, you have to look at the whole genitourinary tract.
Bladder cancer: from a vaccine in the bladder to antibody payloads
Most bladder cancer is urothelial (transitional-cell) carcinoma, and it announces itself with painless blood in the urine. The single most important fork is depth. Non-muscle-invasive disease sits on the surface lining and is treated locally: the tumour is resected through the urethra, then the bladder is bathed with medicine instilled directly into it (intravesical therapy) to stop it coming back. Muscle-invasive or metastatic disease has broken deeper and needs systemic treatment — chemotherapy, immunotherapy and newer targeted agents delivered into the bloodstream.
For high-risk non-muscle-invasive bladder cancer, the standard is intravesical BCG — the same live-attenuated tuberculosis vaccine (Bacillus Calmette–Guérin) covered in the antimicrobials/vaccines section, here instilled into the bladder rather than injected. The bacteria provoke a brisk local immune response that clears residual tumour cells. It is one of medicine's oldest and most effective immunotherapies — a vaccine repurposed as a cancer drug. (Alternatively, an intravesical chemotherapy such as mitomycin C is used.)
When the disease is advanced, the historical backbone is platinum-based chemotherapy — cisplatin-containing regimens, drawing on the same platinum agents detailed in the platinum chapter. But urothelial cancer is now a showcase for newer classes. Immune checkpoint inhibitors — pembrolizumab and atezolizumab from the checkpoint-inhibitors chapter — release the brakes on T-cells and are used when platinum has failed or cannot be given. And the antibody–drug conjugate enfortumab vedotin acts like a guided missile: an antibody homes to a protein (Nectin-4) on the tumour surface and delivers a potent cell-killing payload directly inside it, sparing much of the body.
Bladder cancer is one of the most 'genomically actionable' solid tumours. In tumours carrying an FGFR alteration (fibroblast growth factor receptor), the oral FGFR inhibitor erdafitinib — a targeted kinase inhibitor in the same family as the drugs in the kinase-inhibitors chapter — offers a precision option. The lesson: test the tumour's molecular profile, because it can unlock a pill that a blind chemo choice would miss.
- Most bladder cancer is urothelial carcinoma; painless haematuria is the classic sign.
- Non-muscle-invasive disease: resection + intravesical BCG (or intravesical chemo like mitomycin C).
- Muscle-invasive/advanced: platinum (cisplatin-based) chemotherapy is the backbone.
- Checkpoint inhibitors (pembrolizumab, atezolizumab) when platinum fails or is unsuitable.
- Enfortumab vedotin (antibody–drug conjugate) and erdafitinib (FGFR inhibitor) are targeted options.
Renal cell carcinoma: starve it, then unleash the immune system
The defining fact of kidney cancer is what it is NOT treated with: conventional cytotoxic chemotherapy. Renal cell carcinoma is notably chemo-resistant — the classic cytotoxics that anchor most solid-tumour regimens do very little here. So oncologists exploit two other weaknesses. First, clear-cell kidney tumours are richly vascular; they build their own dense blood supply through the VEGF pathway (vascular endothelial growth factor). Block that pathway and you starve the tumour. Second, they respond strikingly to immunotherapy. Modern first-line treatment combines these ideas.
Anti-angiogenic VEGF-pathway tyrosine kinase inhibitors — sunitinib, pazopanib, cabozantinib — are oral pills that block the receptors driving tumour blood-vessel growth (kinase-inhibitors chapter). Alongside them, immunotherapy: either dual checkpoint blockade (nivolumab + ipilimumab) or, increasingly, a VEGF-TKI paired with a checkpoint inhibitor (for example, axitinib + pembrolizumab). The combination — cut off the blood supply AND lift the immune brakes — has transformed outcomes in advanced kidney cancer without a drop of classic chemotherapy.
Know the VEGF-TKI toxicity signature — it is examined constantly. Hypertension is almost a class effect (the same VEGF blockade that starves the tumour stiffens and constricts normal vessels), which links straight to the cardiovascular section for blood-pressure management. The other classic is hand-foot skin reaction — painful, blistering thickening of the palms and soles. Also watch for proteinuria, hypothyroidism, and diarrhoea. Rising blood pressure on sunitinib is expected, not a surprise.
- Renal cell carcinoma is largely chemo-RESISTANT — conventional cytotoxics are not the treatment.
- Anti-angiogenic VEGF-TKIs (sunitinib, pazopanib, cabozantinib) starve the tumour's blood supply.
- Immunotherapy: nivolumab + ipilimumab, or a VEGF-TKI + checkpoint-inhibitor combination.
- Signature VEGF-TKI toxicities: hypertension and hand-foot skin reaction (also proteinuria, hypothyroidism).
- Localized kidney tumours are often cured by surgery (nephrectomy) alone.
A brief detour: testicular cancer, the curable model
Testicular cancer earns a special mention because it is the opposite of kidney cancer: a solid tumour so chemo-SENSITIVE that it is often curable even when it has already metastasized. Its engine is platinum-based BEP chemotherapy — bleomycin, etoposide and cisplatin — combining the platinum agents, the topoisomerase inhibitor etoposide (anthracyclines/topoisomerase chapter), and bleomycin, whose signature danger is pulmonary fibrosis (bleomycin lung toxicity). Serum tumour markers — AFP (alpha-fetoprotein), hCG (human chorionic gonadotropin) and LDH (lactate dehydrogenase) — are unusually useful here: they help diagnose, stage, and then track response to treatment. (Prostate cancer, the other major genitourinary malignancy, is hormone-driven and covered in its own chapters.)
- Giving conventional cytotoxic chemotherapy for renal cell carcinoma — it is largely chemo-resistant; use anti-angiogenics and immunotherapy instead.
- Forgetting that cisplatin needs adequate renal function — a real hazard when the kidney or urinary tract is the disease site.
- Underusing intravesical BCG in appropriate high-risk non-muscle-invasive bladder cancer — it is a highly effective, guideline-standard immunotherapy.
- Assuming every genitourinary cancer is treated the same — bladder, kidney and testis follow three completely different playbooks.
A patient with metastatic renal cell carcinoma is started on sunitinib. Which adverse effect should you most expect to monitor for?
- Bladder (urothelial) cancer: intravesical BCG for early disease; platinum chemo, checkpoint inhibitors, enfortumab vedotin (ADC) and erdafitinib (FGFR) for advanced.
- Kidney (renal cell) cancer is chemo-resistant — treat with anti-angiogenic VEGF-TKIs plus immunotherapy, not classic cytotoxics.
- Watch VEGF-TKI toxicities: hypertension and hand-foot skin reaction top the list.
- Testicular cancer is the curable-even-when-metastatic model, driven by BEP (bleomycin, etoposide, cisplatin) and tracked by AFP, hCG and LDH.
- NCCN Clinical Practice Guidelines in Oncology — Bladder Cancer.
- NCCN Clinical Practice Guidelines in Oncology — Kidney Cancer.
- NCCN Clinical Practice Guidelines in Oncology — Testicular Cancer.
- ESMO Clinical Practice Guidelines — Bladder cancer, Renal cell carcinoma and Testicular seminoma/non-seminoma.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Targeted therapies, antibody–drug conjugates & immune checkpoint inhibitors.
- DeVita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology — Genitourinary malignancies.
